Scarica l'app Stockscreener
6.68
4.57%
-0.32
Dopo l'orario di chiusura:
6.69
0.01
+0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.00
Aprire:
$7.05
Volume 24 ore:
449.43K
Relative Volume:
0.86
Capitalizzazione di mercato:
$189.87M
Reddito:
$67.22M
Utile/perdita netta:
$-65.78M
Rapporto P/E:
-2.7988
EPS:
-2.3867
Flusso di cassa netto:
$-79.02M
1 W Prestazione:
-6.05%
1M Prestazione:
-7.35%
6M Prestazione:
-61.43%
1 anno Prestazione:
-51.94%
Intervallo 1D:
$6.64
$7.25
Intervallo di 1 settimana:
$6.64
$7.82
Portata 52W:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.68 | 189.87M | 67.22M | -65.78M | -79.02M | -2.3867 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-10-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Downgrade | Citigroup | Buy → Neutral |
| 2025-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-28 | Iniziato | BTIG Research | Buy |
| 2024-08-12 | Iniziato | Leerink Partners | Outperform |
| 2023-12-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-07-24 | Iniziato | William Blair | Outperform |
| 2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Ripresa | Wells Fargo | Overweight |
| 2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
| 2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Iniziato | Wells Fargo | Overweight |
| 2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
| 2020-12-08 | Reiterato | B. Riley Securities | Buy |
| 2020-12-07 | Reiterato | B. Riley Securities | Buy |
| 2020-10-26 | Iniziato | Barclays | Overweight |
| 2020-10-06 | Iniziato | Citigroup | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-30 | Ripresa | ROTH Capital | Buy |
| 2020-07-16 | Iniziato | Raymond James | Outperform |
| 2020-07-13 | Iniziato | B. Riley FBR | Buy |
| 2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-07 | Iniziato | Guggenheim | Buy |
| 2020-02-06 | Iniziato | Guggenheim | Buy |
| 2019-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
The Technical Signals Behind (ARCT) That Institutions Follow - Stock Traders Daily
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - MarketBeat
Patients and scientists join forces for rare disease progress, Arcturus Therapeutics asserts - Traders Union
ARCT Should I Buy - Intellectia AI
Arcturus (ARCT) Q4 2025 Earnings Call Transcript - AOL.com
Stock Report: Can Arcturus Therapeutics Holdings Inc sustain its profitabilityJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Arcturus Therapeutics: Downgrading to "Hold" As CF Program Shifts Population Focus (ARCT) - Seeking Alpha
Arcturus Therapeutics to attend Leerink Partners 2026 Global Healthcare Conference - Traders Union
Q1 EPS Forecast for Arcturus Therapeutics Reduced by Analyst - MarketBeat
Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Citigroup Lowers Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - PharmiWeb.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript - Insider Monkey
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026 - Meyka
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative - simplywall.st
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Piper Sandler Lowers Price Target for Arcturus Therapeutics (ARC - GuruFocus
New nasal vaccine protects lungs for months against viruses, bacteria, and allergens - AOL.com
Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00 - MarketBeat
Arcturus Therapeutics reports financial results and pipeline progress - Traders Union
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates - Investing.com Australia
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcturus Q4 2025 misses expectations, stock drops By Investing.com - Investing.com South Africa
Arcturus Therapeutics Q4 Earnings Call Highlights - MarketBeat
Arcturus Therapeutics falls 5% on weak quarterly revenue - Investing.com
ARCTURUS THERAPEUTICS ($ARCT) Releases Q4 2025 Earnings - Quiver Quantitative
Arcturus (ARCT) Faces Shortfall in Q4 Revenue, Focuses on New Th - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates By Investing.com - Investing.com Canada
Arcturus Therapeutics (NASDAQ:ARCT) Releases Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arcturus Therapeutics falls 5% on weak quarterly revenue By Investing.com - Investing.com Canada
Arcturus Therapeutics 10-K: Revenue $82.0M; EPS not reported - TradingView
KOSTAIVE setback and mRNA pipeline progress at Arcturus (NASDAQ: ARCT) - Stock Titan
Arcturus Therapeutics (ARCT) trims 2025 loss and extends cash runway into Q2 2028 - Stock Titan
Arcturus Therapeutics Q4 Earnings Assessment - Benzinga
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress - Yahoo Finance
Earnings Preview: Arcturus Therapeutics - Benzinga
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings - GuruFocus
Momentum Shift: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn
Bethany Children's Health Center unveils immersive experience plans - AOL.com
Arcturus Therapeutics Holdings Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Arcturus Therapeutics (ARCT) Stock Analysis: Exploring a 304% Potential Upside Amidst Clinical Pipeline Advances - DirectorsTalk Interviews
Arcturus Therapeutics (ARCT) Expected to Post Earnings on Tuesday - MarketBeat
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):